13/09/2024 Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
NRThe Ministry of Health’s Drug Advisory Committee has not recommended cabotegravir with rilpivirine for inclusion on the MOH List of Subsidised Drugs for treating Human Immunodeficiency Virus type 1 (HIV-1) infection. The decision was based on the unfavourable cost-effectiveness of cabotegravir with rilpivirine at the price proposed by the company compared with subsidised oral antiretroviral therapies.